1. The long term follow up period post last dose is changed from " 2 years from screening ” to “6 months post the last dose of immunotherapy”. It is mainly because t o date, safety profile from 19 subjects who have been followed for more than 6 months does not show any study treatment related adverse safety events , therefore it is considered an undue burden on subjects to continue the follow up for an extended time period. Followin g sections of the protocol are affected: • Protocol Synopsis • Tables S1 and S2 Schedule of Events • Section 3, Study Design • Section 6.1.7 Cohort I Long Term Follow Up • Section 6.2.4 Cohort II, Long Term Follow Up 2 Date: 8 April, 2016 v 2.1 INO-3112 UPCC # 39313 / HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol PROTOCOL ACKNOWLEDGEMENT I have read this P rotocol and agree that it contains all necessary details for carrying out the study described. I understand that it must be reviewed by the Institutional Review Board or Independent Ethics Committee overseeing the conduct of the study and approved or given favorable opinion before implementation. The signature of the Principal Investigator and Sponsor below constitute their approval of this protocol and proved the necessary assurances that this study will be conducted according to The Declaration of Helsin ki, GCP, ICH guidelines, local legal and regulatory regulations as well as to all stipulations of the protocol in both the clinical and administrative sections, including statements regarding confidentiality. ______________________ _______________ _________________ Investigator’s printed name Signature Date _________________________________ _________________ Medical Monitor Date Protocol Number: HPV -005 Site Number: Version Number/Version D ate: v2 .1 /8- April -2016 3 Date: 8 April, 2016 v 2.1 INO-3112 UPCC # 39313 / HPV -005 Inovio Pharmaceuticals, Inc Clinical Protocol Table of Contents SUMMARY OF CHANGES .........................................................................................................2 CLINICAL PROTOCOL SYNOPSIS .........................................................................................7 TABLE S1: COHORT I SCHEDULE OF EVENTS ........................................................................ 13 TABLE S2: COHORT II SCHEDULE OF EVENTS ........................................................................ 15 1 INTRODUCTION................................................................................................................17 1.1 BACKGROUND ................................................................................................................ 17 1.1.1 HPV RELATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK ...................... 17 1.1.2 RATIONALE FOR HPV SPECIFIC IMMUNOTHERAPY WITH A THERAPEUTI C HPV VACCINE 18 1.1.3 RATIONALE FOR IMMUNOT HERAPY WITH SYNTHETIC DNA DELIVERED BY ELECTROPORATION ................................................................................................................ 18 1.1.4 RATIONALE FOR ADDITIO N OF IL-12 PLASMID DNA MOLECULAR ADJUVANT ............ 19 1.1.5 RATIONALE FOR ELECTRO PORATION (EP) WITH CELLECTRA® DEVICE ................... 19 1.2 INVESTIGATIONAL AGENTS ............................................................................................